EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cost-Effectiveness Analysis of Pharmacogenomics-Guided Versus Standard Dosing of Warfarin in Patients with Mechanical Prosthetic Heart Valve

Homa Hemati iD, Marzieh Nosrati iD, Mandana Hasanzad iD, Parham Rahmani, Soroush Fariman iD, Mohadese Sarabi, Sepideh Shirvani, Parham Sadeghipour iD, Shekoufeh Nikfar iD

Iranian Journal of Pharmaceutical Research · 14.05.2024 · 23 (1)

DOI: 10.5812/ijpr-143898 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Iranian Journal of Pharmaceutical Research, online erschienen am 14.05.2024. Verfasst von Homa Hemati und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Warfarin is the only approved anticoagulant for antithrombotic treatment in patients with mechanical prosthetic heart valves (MPHV). However, dosing warfarin is challenging due to its narrow therapeutic window and highly variable clinical outcomes. Both low and high doses of warfarin can lead to thrombotic and bleeding events, respectively, with these complications being more severe in individuals with sensitive genetic polymorphisms. Incorporating genetic testing could enhance the accuracy of warfarin dosing and minimize its adverse events.

Objectives

This study aims to evaluate the utilities and cost-effectiveness of pharmacogenomics-guided versus standard dosing of warfarin in patients with MPHV in Iran.

Methods

In this economic evaluation study, a cost-effectiveness analysis was conducted to compare pharmacogenomics-guided versus standard warfarin dosing. Data related to quality of life (QoL) were collected through a cross-sectional study involving 105 randomly selected MPHV patients using the EuroQol-5D (EQ-5D) Questionnaire. Costs were calculated with input from clinical experts and a review of relevant guidelines. Additional clinical data were extracted from published literature. The pharmacoeconomic threshold set for medical interventions within Iran's healthcare system was $1,500. A decision tree model was designed from the perspective of Iran's healthcare system with a one-year study horizon. Sensitivity analyses were also performed to assess the uncertainty of input parameters.

Results

The utility scores derived from the questionnaire for standard and pharmacogenomics-guided warfarin treatments were 0.68 and 0.76, respectively. Genotype-guided dosing of warfarin was more costly compared to the standard dosing ($246 vs $69), and the calculated incremental cost-effectiveness ratio (ICER) was $2474 per quality-adjusted life year (QALY) gained. One-way sensitivity analyses showed that our model is sensitive to the percentage of time in the therapeutic range (PTTR), the cost of genetic tests, and the utility of both pharmacogenomics-guided and standard dosing arms. However, the probabilistic sensitivity analysis demonstrates the robustness of our model.

Conclusions

Warfarin dosing with pharmacogenomics testing is currently not cost-effective. However, if the cost of genotyping tests decreases to $118, the ICER would become cost-effective.

Schlagwörter

Stichwörter der Autor:innen

Cardiovascular DiseaseCost EffectivenessEconomic EvaluationHeart ValvePharmacoeconomicsPharmacogenomicsPrecision MedicineQuality-Adjusted Life YearWarfarin

Autor:innen und Institutionen

  • Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  • Personalized Medicine Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Medical Genomics Research Center, Tehran Medical Sciences Islamic Azad University, Tehran, Iran.
  • Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, University of North Carolina Chapel Hill, NC, USA.
  • Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.

ORCID-Profile: Homa Hemati, Marzieh Nosrati, Mandana Hasanzad, Soroush Fariman, Parham Sadeghipour, Shekoufeh Nikfar

Zitieren

APA

Hemati, H., Nosrati, M., Hasanzad, M., Rahmani, P., Fariman, S., Sarabi, M., Shirvani, S., Sadeghipour, P., & Nikfar, S. (2024). Cost-Effectiveness Analysis of Pharmacogenomics-Guided Versus Standard Dosing of Warfarin in Patients with Mechanical Prosthetic Heart Valve. Iranian Journal of Pharmaceutical Research, 23(1). https://doi.org/10.5812/ijpr-143898

Vancouver

Hemati H, Nosrati M, Hasanzad M, Rahmani P, Fariman S, Sarabi M, et al. Cost-Effectiveness Analysis of Pharmacogenomics-Guided Versus Standard Dosing of Warfarin in Patients with Mechanical Prosthetic Heart Valve. Iranian Journal of Pharmaceutical Research. 2024;23(1). doi:10.5812/ijpr-143898

BibTeX
@article{Hemati2024,
  author = {Hemati, Homa and Nosrati, Marzieh and Hasanzad, Mandana and Rahmani, Parham and Fariman, Soroush and Sarabi, Mohadese and Shirvani, Sepideh and Sadeghipour, Parham and Nikfar, Shekoufeh},
  title = {Cost-Effectiveness Analysis of Pharmacogenomics-Guided Versus Standard Dosing of Warfarin in Patients with Mechanical Prosthetic Heart Valve},
  journal = {Iranian Journal of Pharmaceutical Research},
  year = {2024},
  volume = {23},
  number = {1},
  doi = {10.5812/ijpr-143898}
}
Kostenlos starten →